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Voxel-based morphometryOur understanding of how genotype determines phenotype in primary dystonia is limited. Familial young-
onset primary dystonia is commonly due to the DYT1 gene mutation. A critical question, given the 30%
penetrance of clinical symptoms in DYT1 mutation carriers, is why the same genotype leads to differential
clinical expression and whether non-DYT1 adult-onset primary dystonia, with and without family history
share pathophysiological mechanisms with DYT1 dystonia.
This study examines the relationship between dystonic phenotype and the DYT1 gene mutation by
monitoring whole-brain structure using voxel-based morphometry. We acquired magnetic resonance
imaging data of symptomatic and asymptomatic DYT1 mutation carriers, of non-DYT1 primary dystonia
patients, with and without family history and control subjects with normal DYT1 alleles.
By crossing the factors genotype and phenotype we demonstrate a signiﬁcant interaction in terms of brain
anatomy conﬁned to the basal ganglia bilaterally. The explanation for this effect differs according to both
gene and dystonia status: non-DYT1 adult-onset dystonia patients and asymptomatic DYT1 carriers have
signiﬁcantly larger basal ganglia compared to healthy subjects and symptomatic DYT1 mutation carriers.
There is a signiﬁcant negative correlation between severity of dystonia and basal ganglia size in DYT1
mutation carriers.
We propose that differential pathophysiological and compensatory mechanisms lead to brain structure
changes in non-DYT1 primary adult-onset dystonias and DYT1 gene carriers. Given the range of age of onset,
there may be differential genetic modulation of brain development that in turn determines clinical
expression. Alternatively, a DYT1 gene dependent primary defect of motor circuit development may lead to
stress-induced remodelling of the basal ganglia and hence dystonia.
© 2009 Elsevier Inc. Open access under CC BY license.Introduction
In monogenic neurological disease a single mutation can lead to
varied clinical (phenotypic) manifestations (e.g., Huntington's
disease) (Georgiou et al., 1999); likewise a similar phenotype can
result from a number of different genetic mutations (e.g., hereditary
Alzheimer's diseases) (Nagasaka et al., 2005). The supposition is
that environmental or epigenetic factors modify the expression ofHuman Cognitive and Brain
i).
license.speciﬁc gene mutations and thus determine the ﬁnal phenotype. In
this study, we investigate this hypothesis in primary dystonias
looking for informative differential structural brain endophenotypes
by crossing genetic and clinical factors.
Primary dystonias comprise a broad spectrum of genetic and non-
genetic conditions characterised by dystonia as the only clinical
feature (with or without tremor) and no pathology seen on standard
brain imaging (Fahn et al., 1998). Classiﬁcation according to age of
onset deﬁnes young-onset dystonia with symptom occurrence before
the age of 26 years (Bressman et al., 1989; Kramer et al., 1994) and
those with adult-onset usually between the fourth and sixth decade
(Geyer and Bressman, 2006). The majority of familial young-onset
1142 B. Draganski et al. / NeuroImage 47 (2009) 1141–1147primary dystonia is due to deletion of a GAG trinucleotide in the DYT1
gene on chromosome 9q32–q34 encoding torsinA, a putative
chaperone protein (Gasser et al., 1998; Ozelius et al., 1989). DYT1
dystonia has age-dependent phenotypic penetrance of 25–30% with
marked variability in severity of dystonic signs, ranging from disabling
generalised dystonia to mild focal presentations (Bressman et al.,
1994; Opal et al., 2002). Adult-onset primary dystonia often occurs
sporadically although familial forms of adult-onset dystonia with
genetic linkage (DYT 6, 7, 13) and without are reported (Koukouni
et al., 2007). Adult-onset primary dystonia tends to affect the cranio-
cervical region and remains focal or segmental in distribution (Geyer
and Bressman, 2006).
Lesion studies, neurophysiology experiments, animal and theore-
tical models focus on the basal ganglia, particularly the putamen and
pallidum, as key structures in the pathophysiology of dystonia (Albin
et al., 1989; DeLong, 1990; Mink, 2003). Functional magnetic reso-
nance imaging (fMRI) studies support this notion and demonstrate
correlates of abnormal neural activity in basal ganglia, premotor and
motor related areas (Meunier et al., 2003; van Eimeren and Siebner,
2006). Fluoro-deoxyglucose positron emission tomography (18FDG-
PET) studies of symptomatic and/or asymptomatic DYT1 mutation
carriers show either relative putamen hypermetabolism (Eidelberg et
al., 1998; Trost et al., 2002) or a lack of signiﬁcantmetabolic changes in
the basal ganglia compared to healthy controls (Carbon et al., 2004b).
The fact that bilateral globus pallidus internus (GPi) deep brain
stimulation produces sustained motor improvement in generalised
primary dystonia further conﬁrms the assumption of dysfunctional
basal ganglia in dystonia (Vidailhet et al., 2007).
Although the deﬁnition of primary dystonia implies normal brain
structure, numerous volumetric and computational anatomy studies
of primary adult-onset dystonia demonstrate structural abnormalities
in the basal ganglia and/or associated cortical areas (Black et al., 1998;
Carbon et al., 2004a; Draganski et al., 2003; Egger et al., 2007; Etgen
et al., 2006; Garraux et al., 2004). At themacroscopic level increases in
basal ganglia volume have been interpreted either as plastic change
due to abnormal motor output/sensory input from repetitive move-
ments or dystonic postures (Carbon et al., 2004a; Draganski et al.,
2003; Etgen et al., 2006) or as indicators of developmental
abnormality (Garraux et al., 2004). Up to date, there are no similar
reports regarding in vivo assessment of grey matter structural
abnormalities in DYT1 carriers.
Our aimwas to demonstrate the effect of a DYT1mutation on brain
morphology as a function of clinical signs in symptomatic [S+] and
asymptomatic [S−] DYT1 positive [M+] and negative [M−] subjects.
In addition we included in our analysis a separate cohort of familial
non-DYT1 adult-onset primary dystonia. Based on previous ﬁndings
(Draganski et al., 2003; Egger et al., 2007; Eidelberg et al., 1998; Trost
et al., 2002) our primary hypothesis was that DYT1 mutations
resulting in clinical signs have a speciﬁc impact on basal ganglia
volume. Although our primary hypothesis could be addressed by
region-of-interest (ROI)-based basal ganglia volumetrics, a recent
combined ROI volumetrics/voxel-basedmorphometry (VBM) study in
Huntington's patients has shown advantages of the unbiased whole-
brain VBM technique (Douaud et al., 2006). Therefore, we performed
whole-brain analyses of acquired T1 weighted images using the
validated and automated VBMmethod (Ashburner and Friston, 2000).
Methods
Participants
We recruited: 1) eleven symptomatic DYT1 mutation carriers
[S+M+]; 2) eleven asymptomatic DYT1 mutation carriers [S−M+];
3) ﬁfteen DYT1 mutation negative patients with primary dystonia of
mixed type and positive family history [1S+M−]; 4) fourteen
DYT1 mutation negative adult-onset dystonics without familyhistory [2S+M−] and 5) twenty-eight healthy subjects [S−M−].
We used the Burke–Fahn–Marsden scale (BFM), a validated tool for
assessment of dystonic patients (Burke et al.,1985), to rate the severity
of dystonic signs. We deﬁned clinically signiﬁcant dystonia as the
presence of dystonic signs and a BFM score of 4 or more. Disease
duration estimationwas based either on family and patient's report on
the developmental history or from available medical documentation.
All participants underwent independent clinical assessment by two of
the authors (B.D. and S.A.S.) with review of video assessments by a
third (K.P.B.).
Inclusion criteria for symptomatic [S+M+] DYT1 carriers (8
females, 3 males; mean age 50; range 19–72 years) were (i) positive
genetic analysis for the DYT1 gene mutation, and (ii) presence of
dystonia with BFM score N4. The group of asymptomatic DYT1
subjects [S−M+] (6 females, 5 males; mean age 47; range 30–
76 years) was recruited among family members of the [S+M+]
group. Criteria for inclusion were (i) presence of a DYT1 mutation;
and (ii) absence of dystonic symptoms, at most trivial clinically
detected signs unrecognised by the subjects and a BFM score of 3 or
less. The cohort of subjects with primary dystonia of mixed type plus
positive family history [1S+M−] included patients with focal,
segmental or generalised dystonia (10 females, 5 males; mean age
49.7; range 27–64 years). Inclusion criteria were (i) absence of a
DYT1 mutation; (ii) the presence of focal, segmental or generalised
dystonia; and (iii) a positive family history of dystonia. We aimed to
recruit all symptomatic adult-onset primary dystonia patients with a
positive family history on our books. However, in a few cases
symptomatic relatives were either dead, or contact with them was
lost. The inclusion criteria for the adult-onset primary dystonia
cohort ([2S+M−] 6 females, 8 males; mean age 49.7; range 39–
71 years) were (i) absence of a DYT1 mutation; (ii) the presence of
focal or segmental adult-onset dystonia (age of onset over 35 years);
and (iii) no family history of dystonia. The common inclusion criteria
for all symptomatic patients required (i) no other neurological
disorder than dystonia; (ii) no other cause for dystonia ascertained
by clinical assessment, blood tests or neuroimaging; (iii) no brain,
spinal or peripheral nerve surgery for dystonia; and (iv) no use of
botulinum toxin in the previous 4 months. Clinical details of all
patients are given in Table 1.
Twenty-eight healthy subjects (12 females; mean age 43; range
27–60) with no family history of dystonia and negative DYT1
mutation status were recruited from a departmental register of
volunteers [S−M−]. Inclusion criteria for all subjects comprised
absence of history of psychiatric disorder or brain trauma, no brain,
spinal or peripheral nerve surgery and a normal MRI brain scan. All
subjects gavewritten informed consent prior to MRI-examination and
the local ethics committees approved the study.
Data acquisition
MRI was performed on a Siemens Sonata scanner (Erlangen,
Germany) operating at 1.5 T. A three-dimensional structural MRI scan
was acquired from each subject using a T1-weighted MDEFT sequence
(176 slices, 1 mm thickness, no interslice gap, sagittal acquisition, FoV
224×256 mm, matrix 224×256, TR=20.66 ms, TE=8.42 ms,
TI=640 ms, ﬂip angle 25°, fat saturation, bandwidth 178 Hz/pixel)
(Deichmann et al., 2004).
Image processing
Data processing and analysis were performed with freely available
statistical parametric mapping software (SPM5; Wellcome Trust
Centre for Neuroimaging, London, UK http://www.ﬁl.ion.ucl.ac.uk/
spm) running under Matlab7 (Mathworks, Sherborn, MA, USA). The
T1 weighted scans are partitioned into different tissue classes — grey
matter (GM), white matter (WM) and non-brain voxels (CSF, skull)
Table 1
Clinical data of participants with primary dystonia.
Cohort Case Gender and age (years) Disease duration (years) Site of onset Current distribution BFM Medication
S+M+ 1 M/72 57 R Arm Segmental 9 None
2 F/66 50 R Arm Segmental 14 Trihexyphenidyl
3 F/25 15 R Arm Segmental 16 None
4 M/53 10 Neck, axial Segmental 22 None
5 F/40 32 R Arm, foot Generalised 24 Trihexyphenidyl, Clonazepam
6 F/67 65 R, L Legs Generalised 28 Trihexyphenidyl
7 F/70 26 R Arm, axial Generalised 30 None
8 F/37 26 R Arm Generalised 34 Trihexyphenidyl
9 F/61 54 R Arm Generalised 52 Trihexyphenidyl, Clonazepam
10 M/41 31 L Foot Generalised 66 Trihexyphenidyl, BTX
11 F/19 14 R Foot Generalised 70 BTX
S−M+ 1 F/30 N/A N/A N/A 0 None
2 M/55 N/A N/A N/A 0 None
3 M/46 N/A R Shoulder Focal 1 None
4 M/31 N/A Neck Focal 2 None
5 F/50 N/A R Arm Focal 2 None
6 F/42 35 R Arm Focal 2 None
7 M/35 13 R Arm Focal 2 None
8 F/47 N/A R Arm Focal 2 None
9 F/76 N/A L Shoulder Focal 3 None
10 M/32 6 R Arm Focal 3 None
11 F/76 N/A Neck Focal 3 None
1S+M− 1 F/56 6 Neck Focal 5 BTX
2 F/64 4 Neck Focal 5 BTX
3 M/36 2 Neck Focal 5 BTX
4 F/60 12 Neck Focal 6 BTX
5 F/54 27 Neck Focal 6 BTX
6 M/36 18 Neck Focal 6 BTX
7 F/58 8 Neck Focal 7 BTX
8 F/64 16 Neck Focal 7 BTX
9 F/58 11 Neck Focal 8 BTX
10 M/29 10 R Arm Segmental 9 BTX
11 F/40 5 Neck Segmental 9 BTX
12 F/45 33 Neck Segmental 15 BTX
13 M/64 5 Neck Segmental 15 BTX
14 M/27 5 Neck Segmental 16 BTX
15 F/34 23 R Arm, neck Generalised 32 Trihexyphenidyl, Tetrabenazine
2S+M− 1 M/40 4 Neck Focal 5 BTX
2 M/47 17 Neck Focal 5 BTX
3 F/71 18 Neck Focal 5 BTX
4 F/49 15 Neck Focal 5 BTX, Amitriptyline
5 M/56 11 Neck Focal 5 BTX, Propranolol
6 M/44 3 Neck Focal 5 BTX, Propranolol
7 M/43 4 Neck Focal 5 BTX, Baclofen, Propranolol
8 M/53 8 Neck Focal 5 BTX
9 M/41 4 Neck Focal 6 BTX
10 M/52 3 Neck Focal 6 BTX, Amlodipine, Simvastatin
11 F/58 12 Neck Focal 6 BTX
12 F/46 8 Neck Focal 7 BTX
13 F/48 2.5 Neck Focal 8 BTX
14 M/56 4.5 Neck Focal 8 BTX, Trihexyphenidyl, Clonazepam
[S+M+] — DYT1 mutation positive dystonics.
[S−M+] — DYT1 positive asymptomatic carriers.
[1S+M−] — DYT1 negative dystonics with family history.
[2S+M−] — DYT1 negative dystonics without family history.
BTX — botulinum toxin injections.
N/A — not applicable.
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the “uniﬁed segmentation” approach in SPM5 (Ashburner and Friston,
2005). In order to compare brains of different subjects the resulting
segments are normalised to a population template generated from the
complete dataset using a diffeomorphic registration algorithm
(Ashburner, 2007). This new high-dimensional non-linear warping
algorithm selects conserved features, which are informative for
registration, thus minimising the structural variation among subjects
and providing optimal inter-subject registration. Subsequently, all
images are “modulated” by the Jacobian determinants from the
normalisation steps to preserve initial volumes. Following this the
images are smoothed by convolution with an isotropic Gaussian
kernel of 6 mm full-width at half maximum (FWHM).Statistical analysis
We examined the interaction between DYT1 gene mutation and
dystonic phenotype by creating voxel-based, whole-brain statistical
parametric maps (SPMs) for regional grey matter volume using the
theory of Gaussian random ﬁelds and the general linear model (GLM)
for regional grey matter volume. We used a two-way independent
ANOVA design with a two level phenotype factor — presence or
absence of dystonic symptoms [S+ and S−] and a two level genotype
factor — presence or absence of the DYT1 mutation [M+ and M−].
Given the dystonia subtype dependent differences between groups
we included disease duration, severity of dystonic symptoms (indexed
by BFM score), age, gender and total intracranial volume (TIV) as
1144 B. Draganski et al. / NeuroImage 47 (2009) 1141–1147“nuisance” variables to control for any independent effects on our
ﬁndings and to ensure that the analysis identiﬁes regionally speciﬁc
“non-global” effects (Ashburner and Friston, 2000). Considering the
signiﬁcant correlation between the group means and the variable
disease duration (rN .7) and severity of dystonic signs (rN .6) we
orthogonalized them using a Gram–Schmidt process implemented
in SPM. All analyses were performed using the same model that
included all ﬁve groups: 1) symptomatic [S+M+] and 2) asympto-
matic [S−M+] DYT1 mutation carriers, DYT1 negative adult-onset
dystonics 3) with [1S+M−] and 4) without positive family history
[2S+M−] and 5) mutation negative controls [S−M−].
Additionally, we modelled the mean-corrected covariates repre-
senting severity of clinical symptoms (BFM score) and disease
duration for the DYT1 positive group and for both DYT1 negative
symptomatic cohorts in separate multiple regression analyses.
Signiﬁcance levels were set at pb0.05 after family wise error
(FWE) correction for multiple comparisons for whole-brain
volumes. We also used a small volume correction (SVC), thresholded
at pb0.05 (FWE correction), comprising the whole volume of the
basal ganglia, because our a priori hypothesis justiﬁed limiting the
search volume to the basal ganglia. The anatomical location and
volume of the basal ganglia were deﬁned from the WFU-Pick brain
atlas (Maldjian et al., 2003).
Results
Clinical assessment
The clinical details of each cohort are given in Table 1. The BFM
score has the range between 0 and 150; higher BFM score indicates
more severe dystonic symptoms.Fig. 1. Statistical parametric maps (SPMs) of structural changes in grey matter representin
[S+M+]) vs ([S−M+]–[S−M−])) and (([2S +M−]–[S+M+]) vs ([S−M+]–[S−M−])
image at a threshold of pb0.001, uncorrected. Parameter estimates at voxel maxima in th
interaction between factors genotype [DYT1 M+ or M−] and phenotype [S+ or S−]. Fam
and 2 in the interaction plot. (E) Voxels displayed on “glass brain” showsigniﬁcant effects at
[x y z] refer to the Montreal Neurological Institute (MNI) standard stereotactic space. [S+M
dystonia. [S−M+] — DYT1 mutation positive asymptomatic carriers. [S−M−] — Healthy coInteraction analysis
We found a signiﬁcant negative crossover interaction between the
factors DYT1-genotype and dystonic phenotype in both putamen and
pallidum bilaterally (pb0.05, FWE correction). The SPMs, super-
imposed on a T1-weighted anatomical image, warped into standard
stereotactic space, are presented in Fig.1 and results are shown inTable
2. There were no statistically signiﬁcant main effects of phenotype or
genotype (i.e.,{[S+M+]+[1 or 2S+M−] vs [S−M+]+[S−M−]} and
{[S+M+]+[S−M+] vs [1 or 2S+M−]+[S−M−]}).
A descriptive analysis of simple effects underlying the interaction
shows that the DYT1 mutation has an inﬂuence on putamen volume
measurements bilaterally in symptomatic patients ([1 or 2S+M−] vs
[S+M+]) and in asymptomatic subjects ([S−M+] vs [S−M−]),
(pb0.05, FWE correction). Asymptomatic DYT1 mutation carriers and
both groups of non-DYT1 primary dystonia patients have signiﬁcantly
greater putamen volumes than either normal subjects or symptomatic
DYT1 carriers. The presence of symptoms, consequently, has an effect
on putamen volume in those with the DYT1 mutation ([S−M+] vs
[S+M+]), non-symptomatic carriers having the greater volume. In
the absence of a DYT1 mutation symptomatic adult-onset dystonic
patients have greater greymatter volume than normal controls in both
putamen and pallidum ([1 or 2S+M−] vs [S−M−]). Additionally, a
bilateral grey matter volume increment is found in somatosensory
cortex in asymptomatic DYT1 carriers [S−M+] compared to healthy
controls [S−M−], (pb0.05, FWE correction), (Table 2).
Regression analysis
The secondary multiple regression analysis demonstrated in the
DYT1 mutation carriers (Fig. 2) a signiﬁcant negative correlationg the anatomical expression of both genotype-phenotype interactions: (([1S +M−]–
). (A–C) For presentation purposes, the SPMs are superimposed on a T1 weighted
e left putamen [−26 −5 −4]. (D and F) Bar plot and interaction plot of crossover
ilial [1S+M−] and sporadic [2S+M−] non-DYT1 dystonics labelled with numbers 1
pb0.05 after FWE correction formultiple comparisons over thewhole brain. Coordinates
+] — DYT1 mutation positive dystonics. [1S+M−] — Familial DYT1 mutation negative
ntrols. [2S+M−] — Sporadic DYT1 mutation negative dystonia.
Table 2
Summary of VBM results (whole brain PFWEb0.05).
Analysis Region Left hemisphere
coordinates (mm)
Z-score Right hemisphere
coordinates (mm)
Z-score
x y z x y z
Interaction
(([1S +M−]–[S+M+]) vs ([S−M+]–[S−M−])) Putamen −26 −5 −4 4.9 29 4 1 4.9
Gpi⁎ −14 −2 −13 3.8 13 −1 −11 3.2
(([2S +M−]–[S+M+]) vs ([S−M+]–[S−M−])) Putamen⁎ −23 −2 0 4.5 29 −5 1 4.6
Gpi⁎ −15 −1 −10 3.5 15 3 −10 3.1
Simple effects
(S+M+)b(1S+M−) Putamen⁎ −30 −9 −2 3.9 31 −8 4 3.4
(S+M+)b(2S+M−) Putamen⁎ −29 −2 12 3.1 30 0 11 3.2
(S−M+)N(S−M−) Putamen⁎ −27 5 −2 4.2 29 1 −3 4.5
Si/Sii⁎ −43 −55 39 3.6 41 −36 49 4.9
(S+M+)b(S−M+) Putamen⁎ −24 −4 0 3.6 29 −5 1 3.8
Si/Sii⁎ 41 −36 49 3.8
(1S +M−)N(S−M−) Putamen⁎ −30 −3 −6 4 37 −3 −7 4.4
(2S +M−)N(S−M−) Putamen⁎ −18 3 0 3.1 31 −1 −2 3.4
Correlation
BFM – (S+M+) and (S−M+) Putamen⁎ −29 2 4 4.6 31 0 1 4.2
Results with asterisk (⁎) are corrected using a small volume correction (SVC for the whole basal ganglia volume, PFWEb0.05). Coordinates [x y z] refer to the Montreal Neurological
Institute (MNI) standard stereotactic space). GPi — internal segment of globus pallidus; SI/II — primary/secondary sensory cortex.
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volume bilaterally (pb0.05, FWE correction). The more severe the
dystonia, the smaller the volume of the putamen. The mean dystonia
severity score (BFM) in the [S+M+] group was 33.2 with a range of 9
to 70, in the [S−M+] −1.9 with a range of 0 to 3. No signiﬁcant
correlations were found between grey matter volume and clinical
variables (BFM score, disease duration) in the groups of adult-onset
primary dystonia patients.
Discussion
Our results ﬁnd differential changes of brain structure in primary
dystonia by demonstrating clear evidence for an interaction between
clinical phenotype (dystonia) and genotype (DYT1 mutation status).
We ﬁnd positive proof for a differential impact of DYT1 genotype on
basal ganglia volume depending on the presence or absence of
dystonia such that the putamen bilaterally are larger in asymptomaticFig. 2. Correlation between severity of dystonia (BFM rating scale) and structural
changes in the putamen (in red — right putamen, in blue — left putamen) in the group
of DYT1 gene mutation carriers [M+], (pb0.001 two-tailed Pearson correlation test).
The effect size was estimated at voxel peaks in the right [x y z; 31 0 1] and left putamen
[x y z;−29 2 4]. Coordinates [x y z] refer to the Montreal Neurological Institute (MNI)
standard stereotactic space).DYT1 carriers than in symptomatic DYT1 patients. Further, greymatter
volume of the basal ganglia in asymptomatic DYT1 carriers resembles
that of non-DYT1 adult-onset primary dystonia. This result is
replicated in a separate cohort of familial non-DYT1 dystonics. We
conﬁrm the unique signiﬁcance of this result (despite the presence of
subtle, clinically insigniﬁcant dystonic signs in asymptomatic DYT1
carriers) by showing in additional regression analysis a tight and
signiﬁcant negative linear correlation between symptom severity and
putamen volume bilaterally across the whole DYT1 positive
population.
How are we to interpret these novel ﬁndings? One hypothesis is
that the aetiology of basal ganglia volume change in DYT1 mutation
carriers is different from that brought about by the causative gene(s)/
environmental inﬂuences in non-DYT1 adult-onset primary dystonia.
There is some rationale for this hypothesis in that histological studies
have revealed a neurodegenerative process in DYT1 dystonia
(McNaught et al., 2004), and lack of such degeneration in primary
non-DYT1 adult-onset dystonia (Holton et al., 2008). Further, there
are numerous abnormalities on electrophysiological and psycho-
physical tests that are similar in symptomatic and asymptomatic DYT1
mutation carriers and patients with non-DYT1 adult-onset primary
dystonia (and their unaffected relatives) (Edwards et al., 2006;
Edwards et al., 2003; Fiorio et al., 2007; Quartarone et al., 2005).
Conversely, particular abnormalities are conﬁned to symptomatic
DYT1 carriers. This growing body of evidence suggests a complex set
of pathophysiological changes in all patients with primary dystonia.
There are some abnormalities that are not sufﬁcient on their own to
cause dystonia and therefore also occur in asymptomatic DYT1
mutation carriers or unaffected relatives of patients with adult-
onset dystonia. However, there are some abnormalities (e.g. excessive
response to a plastic force), which appear necessary for the
production of clinical symptoms.
Basal ganglia dysfunction driven by aberrant plasticity phenomena
partially due to dopamine dysfunction is thought to be a major factor
contributing to dystonia (Baumer et al., 2007; Quartarone et al., 2005;
Utter and Basso, 2008). The impact of compensation for motor loop
dysfunction could translate into morphological changes in these
circuits. This hypothesis would suggest that putamen enlargement in
asymptomatic DYT1 mutation carriers is perhaps a compensatory
phenomenon, which does not occur in symptomatic gene carriers. The
adult-onset primary dystonia non-DYT1 patients included in our
study in general have mild dystonia (most with a BFM score of 5–10)
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achieved remarkably good compensation for whatever underlying
defect is the cause of their dystonia. Asymptomatic DYT1 mutation
carriers are an even better example of such compensation with no or
negligible clinical dystonia despite their genetic predisposition. All
these subjects have enlarged putamen bilaterally. The symptomatic
DYT1 mutation carriers, who have dystonia of young-onset, often of
marked severity, have signiﬁcantly smaller putamen volume, and the
size of the putamen bilaterally is negatively correlated with the
severity of symptoms. Given these ﬁndings and the data reviewed
above, an alternative hypothesis is therefore that putaminal enlarge-
ment may be a general compensatory response to a variety of gene
mutations, including the DYT1 mutation that predisposes to dystonia.
If this compensation occurs, as in asymptomatic DYT1 carriers and
adult-onset non-DYT1 primary dystonia, then dystonia either does not
occur, or occurs late and is limited in distribution and severity. If it
does not occur, as in symptomatic DYT1 mutation carriers, then
dystonia occurs early in life, may affect many body parts and may be
severe.
Conversely, in adult-onset non-DYT1 primary dystonia, putamen
volume increase may be part of the pathological process leading to
symptom production. As support for this hypothesis, a recent study
has found that putamen volumes were enlarged in a mixed group of
patients with predominantly non-DYT1 dystonia (Egger et al., 2007).
The lack of correlation between clinical symptom severity and basal
ganglia volume in both non-DYT1 adult-onset primary dystonia
cohorts contrasts with a signiﬁcant correlation in DYT1 patients,
which also supports the idea of a developmental pathological insult,
unrelated to the clinical course of disease. Our results with basal
ganglia volume reduction in DYT1 dystonics have the implication that
there is something particular about DYT1 mutation carriers. This idea
implies that putaminal enlargement could be protective against the
development of clinical dystonia in DYT1 carriers. In non-DYT1 adult-
onset primary dystonia, putaminal enlargement may be reﬂecting a
pathological process that eventually leads to symptoms of dystonia.
A third hypothesis is that it is the early age at onset of symptoms in
symptomatic DYT1 mutation carriers that is responsible for the
difference in their putamen volume compared to the other patient
groups. DYT1 mutation related dystonic signs developed in our cohort
at a mean age of 15.5 years while the familial primary non-DYT1
dystonia onset clustered around the age of 36 years and the adult-
onset non-familial— around the age of 42 years. The putamen volume
decrement in symptomatic DYT1 carriers is consistent with a recent
report pointing towards a pivotal role for torsinA, encoded by the
defective DYT1 gene, in stress-induced remodelling of basal ganglia
circuits (Zhao et al., 2008). The supposition here is that we observe in
DYT1 mutation carriers the net effect of two different processes —
primary basal ganglia enlargement caused by the DYT1 gene and
stress-induced remodelling of striatal circuits related to clinical
expression of symptoms. Such a formulation could explain the
symptom manifestations, gene mutation status and the interaction
between them in terms of the anatomical endophenotypes we have
shown. However, the absence of similar changes in the familial non-
DYT1 early onset dystonics is a factor against this idea.
An apparent experimental limitation is that other unknowngenetic
factors may have contributed to the differential anatomical results. In
our study the interaction is observed between DYT1 carriers and two
groups of non-DYT1 dystonics — one is familial with an unknown
genotype and the other has no evidence of anymonogenic association.
This ﬁnding strengthens the idea that the DYT1 gene mutation is
speciﬁcally responsible for the differential anatomical and pathophy-
siological expression. In addition, we corrected for any independent
effect of unmatched patient variables to the results by including age,
gender, disease duration and symptom severity in our analysis. The
higher usage of anti-cholinergic medication in symptomatic DYT1
mutation carriers (see Table 1) represents another potential confound.Anti-cholinergic drugs are associated with cortical hypometabolism
(Takahashi et al., 1999), however there are no morphometric studies
suggestive of a speciﬁc effect on brain structure. The signiﬁcant
negative linear correlation between symptom severity and putamen
volume bilaterally suggests a unique contribution of dystonic
phenotype to the demonstrated morphometric changes.
In conclusion, we have demonstrated different patterns of basal
ganglia volume change in patients with adult-onset primary dystonia,
non-symptomatic and symptomatic DYT1 mutation carriers. These
constitute differential anatomical endophenotypes. Our results
suggest a different pathophysiological process in DYT1 dystonia
compared to other forms of primary dystonia and also indicate that
increases in putamen volume are not always associated with
clinically symptomatic dystonia.
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